Provenge, first autologous cellular immunotherapy to prolong survival in prostate cancer
PROVENGE(R) (sipuleucel-T) demonstrated a statistically significant improvement in overall survival compared to control in men with asymptomatic or minimally symptomatic metastatic castration resistant prostate cancer New England Journal of Medicine Publishes Data from Pivotal Phase 3 PROVENGE IMPACT Study First Autologous Cellular Immunotherapy to Prolong Survival in Cancer SEATTLE, July 28, 2010 /PRNewswire via COMTEX/
Read more →